The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the v...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Brain, Behavior, & Immunity - Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666354621001848 |
| _version_ | 1819174606620065792 |
|---|---|
| author | M.D. Maldonado J. Romero-Aibar |
| author_facet | M.D. Maldonado J. Romero-Aibar |
| author_sort | M.D. Maldonado |
| collection | DOAJ |
| description | Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection. Methods: Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic. Results: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV). Discussion: The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency. |
| first_indexed | 2024-12-22T20:41:39Z |
| format | Article |
| id | doaj.art-23be77dddc9e42f0b6e57073acd6fead |
| institution | Directory Open Access Journal |
| issn | 2666-3546 |
| language | English |
| last_indexed | 2024-12-22T20:41:39Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain, Behavior, & Immunity - Health |
| spelling | doaj.art-23be77dddc9e42f0b6e57073acd6fead2022-12-21T18:13:19ZengElsevierBrain, Behavior, & Immunity - Health2666-35462021-12-0118100381The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virusM.D. Maldonado0J. Romero-Aibar1Department of Medical Biochemistry, Molecular Biology, and Immunology, University of Seville Medical School, Spain; Corresponding author. Department of Medical Biochemistry, Molecular Biology, and Immunology, University of Sevilla, Medical School, Avda. Sánchez Pizjuán 4, 41009. Seville, Spain.Superior Laboratory Technician, Department of External Analysis Service, IRNAS (CSIC) Seville, SpainBackground: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection. Methods: Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic. Results: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV). Discussion: The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency.http://www.sciencedirect.com/science/article/pii/S2666354621001848The anti-SARS-CoV-2 vaccinesmRNA-based vaccinesHerpes zoster infectionImmune system |
| spellingShingle | M.D. Maldonado J. Romero-Aibar The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus Brain, Behavior, & Immunity - Health The anti-SARS-CoV-2 vaccines mRNA-based vaccines Herpes zoster infection Immune system |
| title | The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus |
| title_full | The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus |
| title_fullStr | The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus |
| title_full_unstemmed | The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus |
| title_short | The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus |
| title_sort | pfizer bnt162b2 mrna based vaccine against sars cov 2 may be responsible for awakening the latency of herpes varicella zoster virus |
| topic | The anti-SARS-CoV-2 vaccines mRNA-based vaccines Herpes zoster infection Immune system |
| url | http://www.sciencedirect.com/science/article/pii/S2666354621001848 |
| work_keys_str_mv | AT mdmaldonado thepfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus AT jromeroaibar thepfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus AT mdmaldonado pfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus AT jromeroaibar pfizerbnt162b2mrnabasedvaccineagainstsarscov2mayberesponsibleforawakeningthelatencyofherpesvaricellazostervirus |